{"hands_on_practices": [{"introduction": "The efficacy of a checkpoint inhibitor is fundamentally tied to its ability to bind its molecular target. This exercise [@problem_id:4931191] walks you through the core principles of receptor pharmacology, guiding you to derive the relationship between drug concentration and target occupancy from first principles. Mastering this allows you to calculate the equilibrium dissociation constant ($K_{D}$), a key measure of a drug's potency, and determine the concentration required to achieve a desired level of target engagement.", "problem": "An anti-Programmed cell death protein 1 (PD-1) monoclonal antibody (mAb) is being developed to block inhibitory signaling on T cells in the tumor microenvironment. Consider the reversible binding reaction between free ligand (the mAb), denoted by $L$, and free receptor (PD-1), denoted by $R$, forming the ligand–receptor complex $LR$. Assume monovalent binding with one ligand binding site per receptor and a well-mixed system at equilibrium. The fundamental base for this problem is the law of mass action for elementary reactions and the definition of the equilibrium dissociation constant.\n\nYou are given the kinetic parameters: $k_{on} = 10^{5}\\ \\text{M}^{-1}\\text{s}^{-1}$ and $k_{off} = 10^{-4}\\ \\text{s}^{-1}$. The PD-1 surface density is $5000$ molecules per T cell. Starting from the mass-action description of the reaction $L + R \\rightleftharpoons LR$, and using the definition of the equilibrium dissociation constant $K_{D}$ in terms of $k_{on}$ and $k_{off}$, derive the equilibrium fractional occupancy $f$ (the fraction of total receptors occupied) as a function of the free ligand concentration $[L]$ and $K_{D}$. Then, using this relationship, compute:\n\n1. The equilibrium dissociation constant $K_{D}$.\n2. The free ligand concentration $[L]$ required to achieve a fractional occupancy of $f = 0.90$ at equilibrium.\n\nAssume negligible ligand depletion by receptors so that the free ligand concentration $[L]$ is well-approximated by the total applied ligand concentration; justify in your reasoning whether and how the given PD-1 surface density affects the occupancy expression under this assumption.\n\nExpress both numerical answers in nanomolar, rounding to three significant figures. Do not include units in your final boxed answer; the required unit is specified here.", "solution": "The problem statement is first validated for scientific soundness, completeness, and objectivity.\n\n**Step 1: Extract Givens**\n- Reaction: $L + R \\rightleftharpoons LR$, where $L$ is a free mAb ligand, $R$ is a free PD-1 receptor, and $LR$ is the ligand-receptor complex.\n- Binding characteristics: Monovalent binding (one ligand site per receptor), well-mixed system, at equilibrium.\n- Kinetic rate constants: $k_{on} = 10^{5}\\ \\text{M}^{-1}\\text{s}^{-1}$ (association rate constant) and $k_{off} = 10^{-4}\\ \\text{s}^{-1}$ (dissociation rate constant).\n- Receptor surface density: $5000$ molecules per T cell.\n- Assumption: Negligible ligand depletion, so free ligand concentration $[L]$ is approximated by the total applied ligand concentration.\n- Objective 1: Derive the fractional occupancy $f$ as a function of $[L]$ and the equilibrium dissociation constant $K_{D}$.\n- Objective 2: Compute the numerical value of $K_{D}$.\n- Objective 3: Compute the free ligand concentration $[L]$ required to achieve a fractional occupancy of $f = 0.90$.\n- Output requirements: Express numerical answers in nanomolar (nM) and round to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is grounded in the fundamental principles of chemical kinetics and receptor theory, specifically the law of mass action applied to ligand-receptor binding. The context (PD-1 checkpoint inhibition) is a core topic in modern pharmacology and oncology. The given kinetic parameters are physically realistic for monoclonal antibody interactions. The problem is scientifically sound.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary information ($k_{on}$, $k_{off}$, target occupancy $f$) to derive the requested expression and calculate the required values. The derivation and subsequent calculations lead to a unique, stable solution.\n- **Objectivity**: The problem is stated using precise, objective scientific language, free of ambiguity or subjective claims.\n- **Verdict**: The problem is valid. It is a standard, formalizable problem in biophysical chemistry and pharmacology. The inclusion of the PD-1 surface density alongside the \"negligible depletion\" assumption does not represent a contradiction but rather requires a justification of why the surface density is not needed for the calculation, a task explicitly requested in the problem statement.\n\n**Solution Derivation**\n\nThe reversible binding reaction is given by:\n$$\nL + R \\underset{k_{off}}{\\stackrel{k_{on}}{\\rightleftharpoons}} LR\n$$\nAccording to the law of mass action, the rate of formation of the ligand-receptor complex, $v_{f}$, is proportional to the concentrations of the free ligand $[L]$ and free receptor $[R]$:\n$$\nv_{f} = k_{on} [L] [R]\n$$\nThe rate of dissociation of the complex, $v_{d}$, is proportional to the concentration of the complex $[LR]$:\n$$\nv_{d} = k_{off} [LR]\n$$\nAt equilibrium, the rate of formation equals the rate of dissociation:\n$$\nv_{f} = v_{d}\n$$\n$$\nk_{on} [L] [R] = k_{off} [LR]\n$$\nThe equilibrium dissociation constant, $K_{D}$, is defined as the ratio of the dissociation rate constant to the association rate constant:\n$$\nK_{D} = \\frac{k_{off}}{k_{on}}\n$$\nBy rearranging the equilibrium condition, we can relate $K_{D}$ to the concentrations of the species:\n$$\nK_{D} = \\frac{k_{off}}{k_{on}} = \\frac{[L][R]}{[LR]}\n$$\nThe total concentration of receptors, $[R_{T}]$, is the sum of the free receptors $[R]$ and the bound receptors $[LR]$:\n$$\n[R_{T}] = [R] + [LR]\n$$\nFractional occupancy, $f$, is defined as the fraction of total receptors that are occupied by the ligand:\n$$\nf = \\frac{[LR]}{[R_{T}]}\n$$\nTo derive $f$ as a function of $[L]$ and $K_{D}$, we first express $[R]$ in terms of $[R_T]$ and $[LR]$:\n$$\n[R] = [R_{T}] - [LR]\n$$\nSubstituting this into the expression for $K_{D}$:\n$$\nK_{D} = \\frac{[L]([R_{T}] - [LR])}{[LR]}\n$$\nNow, we solve for the ratio $\\frac{[LR]}{[R_{T}]}$:\n$$\nK_{D} [LR] = [L][R_{T}] - [L][LR]\n$$\n$$\nK_{D} [LR] + [L][LR] = [L][R_{T}]\n$$\n$$\n[LR](K_{D} + [L]) = [L][R_{T}]\n$$\n$$\n\\frac{[LR]}{[R_{T}]} = \\frac{[L]}{[L] + K_{D}}\n$$\nThus, the expression for fractional occupancy is:\n$$\nf = \\frac{[L]}{[L] + K_{D}}\n$$\nThis is the required relationship. It is a form of the Hill-Langmuir equation for a system with a single class of independent binding sites (Hill coefficient of $1$).\n\n**Justification for PD-1 Surface Density**\nThe problem asks to justify how the PD-1 surface density ($5000$ molecules per T cell) affects the occupancy expression under the assumption of negligible ligand depletion.\nThe derived expression $f = \\frac{[L]}{[L] + K_{D}}$ depends only on the free ligand concentration $[L]$ and the dissociation constant $K_{D}$. It does not explicitly involve the total receptor concentration $[R_{T}]$. The surface density information would be used to calculate $[R_{T}]$ if the cell density were provided.\nThe assumption of \"negligible ligand depletion\" means that the concentration of bound ligand, $[LR]$, is insignificant compared to the total ligand concentration, $[L_T]$. Therefore, the free ligand concentration at equilibrium, $[L]$, can be accurately approximated by the total applied concentration: $[L] \\approx [L_T]$. This condition holds when $[L_T] \\gg [R_T]$.\nBecause we assume $[L]$ is a known, independent variable (approximated by the total applied concentration), the calculation of $[R_T]$ from the surface density is unnecessary to determine the fractional occupancy $f$. In this regime, there is a vast excess of ligand, and the fraction of occupied receptors is determined solely by the free ligand concentration and the intrinsic binding affinity ($K_D$), not by the number of receptors present. If ligand depletion were significant (i.e., $[L_T] \\sim [R_T]$), we would need to solve a more complex system of equations where $[L] = [L_T] - [LR]$, and the value of $[R_T]$ (and thus the surface density) would be essential.\n\n**Calculations**\n\n1.  **Compute the equilibrium dissociation constant $K_{D}$**:\n    Using the definition $K_{D} = \\frac{k_{off}}{k_{on}}$ and the given kinetic parameters:\n    $$\n    K_{D} = \\frac{10^{-4}\\ \\text{s}^{-1}}{10^{5}\\ \\text{M}^{-1}\\text{s}^{-1}} = 10^{-9}\\ \\text{M}\n    $$\n    To express this in nanomolar (nM), we use the conversion $1\\ \\text{nM} = 10^{-9}\\ \\text{M}$.\n    $$\n    K_{D} = 1.00 \\times 10^{-9}\\ \\text{M} = 1.00\\ \\text{nM}\n    $$\n    Rounded to three significant figures, $K_D$ is $1.00\\ \\text{nM}$.\n\n2.  **Compute the free ligand concentration $[L]$ for $f = 0.90$**:\n    We rearrange the fractional occupancy equation to solve for $[L]$:\n    $$\n    f = \\frac{[L]}{[L] + K_{D}} \\implies f([L] + K_{D}) = [L]\n    $$\n    $$\n    f[L] + f K_{D} = [L]\n    $$\n    $$\n    f K_{D} = [L] - f[L] = [L](1 - f)\n    $$\n    $$\n    [L] = K_{D} \\frac{f}{1 - f}\n    $$\n    Now, substitute the values $K_{D} = 10^{-9}\\ \\text{M}$ and $f = 0.90$:\n    $$\n    [L] = (10^{-9}\\ \\text{M}) \\times \\frac{0.90}{1 - 0.90} = (10^{-9}\\ \\text{M}) \\times \\frac{0.90}{0.10} = (10^{-9}\\ \\text{M}) \\times 9\n    $$\n    $$\n    [L] = 9 \\times 10^{-9}\\ \\text{M}\n    $$\n    Converting to nanomolar:\n    $$\n    [L] = 9.00\\ \\text{nM}\n    $$\n    Rounded to three significant figures, the required ligand concentration is $9.00\\ \\text{nM}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1.00 & 9.00\n\\end{pmatrix}\n}\n$$", "id": "4931191"}, {"introduction": "While understanding equilibrium is crucial, the speed at which a drug binds its target can be just as important for its clinical effect. This practice [@problem_id:4931253] moves beyond the static picture of equilibrium to explore the dynamics of receptor binding over time. By deriving and solving the kinetic equations, you will see how the association ($k_{\\mathrm{on}}$) and dissociation ($k_{\\mathrm{off}}$) rate constants determine how quickly a therapeutic antibody can occupy its target on T cells.", "problem": "A Programmed Cell Death Protein 1 (PD-1) receptor on T cells is targeted by a checkpoint-inhibitor monoclonal antibody (mAb) to block Programmed Death-Ligand 1 (PD-L1) signaling. Consider a single binding site per receptor. The antibody, denoted as $A$, binds the receptor $R$ to form a complex $AR$ under mass-action kinetics, with association rate constant $k_{\\mathrm{on}}$ and dissociation rate constant $k_{\\mathrm{off}}$. The total receptor concentration is $[R]_{\\mathrm{tot}}$, the free receptor concentration is $[R]$, the bound receptor concentration is $[AR]$, and the free antibody concentration is $C$. Assume that during the time of interest the antibody concentration $C$ is held constant by infusion, receptor synthesis and internalization are negligible, and the system is isothermal and well-mixed.\n\nStarting from the mass-action law and the definition of the equilibrium dissociation constant $K_D = \\frac{k_{\\mathrm{off}}}{k_{\\mathrm{on}}}$, derive the fraction of receptor occupancy at equilibrium, defined as $\\theta_{\\mathrm{eq}} = \\frac{[AR]_{\\mathrm{eq}}}{[R]_{\\mathrm{tot}}}$, under the rapid equilibrium assumption. Then, by writing the ordinary differential equation for $[AR](t)$ under constant $C$ and solving it with the initial condition $[AR](0) = 0$, obtain the time-dependent occupancy $\\theta(t)$ and the minimal time $t_{0.9}$ required to reach $\\theta(t) = 0.9\\,\\theta_{\\mathrm{eq}}$. Briefly, explain how a small $k_{\\mathrm{on}}$ (slow association) affects the approach to equilibrium.\n\nFinally, for a hypothetical engineered PD-1 mAb with slow association, use $k_{\\mathrm{on}} = 1.0 \\times 10^{4} \\,\\mathrm{M}^{-1}\\mathrm{s}^{-1}$, $k_{\\mathrm{off}} = 1.0 \\times 10^{-3} \\,\\mathrm{s}^{-1}$, and a maintained interstitial antibody concentration $C = 30 \\,\\mathrm{nM}$ (that is, $C = 30 \\times 10^{-9} \\,\\mathrm{M}$). Compute $t_{0.9}$ and express your final answer in minutes. Round your answer to three significant figures. The final numerical answer must be given as a unitless decimal number representing minutes.", "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded in the principles of mass-action kinetics and receptor pharmacology, well-posed with a clear objective and sufficient information, and uses objective, unambiguous language. We may therefore proceed with the solution.\n\nThe problem asks for several derivations and a final numerical calculation regarding the binding kinetics of a monoclonal antibody ($A$) to its receptor ($R$).\n\nFirst, we derive the fraction of receptor occupancy at equilibrium, $\\theta_{\\mathrm{eq}}$. The binding reaction is given as:\n$$ A + R \\underset{k_{\\mathrm{off}}}{\\stackrel{k_{\\mathrm{on}}}{\\rightleftharpoons}} AR $$\nUnder mass-action kinetics, the rate of formation of the complex $[AR]$ is $k_{\\mathrm{on}}[A][R]$ and the rate of its dissociation is $k_{\\mathrm{off}}[AR]$. At equilibrium, these rates are equal:\n$$ k_{\\mathrm{on}}[A]_{\\mathrm{eq}}[R]_{\\mathrm{eq}} = k_{\\mathrm{off}}[AR]_{\\mathrm{eq}} $$\nThe problem states that the free antibody concentration is held constant at $C$, so $[A]_{\\mathrm{eq}} = C$. The equilibrium relationship is thus:\n$$ k_{\\mathrm{on}} C [R]_{\\mathrm{eq}} = k_{\\mathrm{off}}[AR]_{\\mathrm{eq}} $$\nRearranging this equation and using the definition of the equilibrium dissociation constant, $K_D = \\frac{k_{\\mathrm{off}}}{k_{\\mathrm{on}}}$, we get:\n$$ K_D = \\frac{[R]_{\\mathrm{eq}} C}{[AR]_{\\mathrm{eq}}} $$\nThe total receptor concentration, $[R]_{\\mathrm{tot}}$, is the sum of free and bound receptors: $[R]_{\\mathrm{tot}} = [R] + [AR]$. At equilibrium, this is $[R]_{\\mathrm{tot}} = [R]_{\\mathrm{eq}} + [AR]_{\\mathrm{eq}}$. We can express the free receptor concentration at equilibrium as $[R]_{\\mathrm{eq}} = [R]_{\\mathrm{tot}} - [AR]_{\\mathrm{eq}}$. Substituting this into the expression for $K_D$:\n$$ K_D = \\frac{([R]_{\\mathrm{tot}} - [AR]_{\\mathrm{eq}}) C}{[AR]_{\\mathrm{eq}}} $$\nWe solve for $[AR]_{\\mathrm{eq}}$:\n$$ K_D [AR]_{\\mathrm{eq}} = C[R]_{\\mathrm{tot}} - C[AR]_{\\mathrm{eq}} $$\n$$ (K_D + C)[AR]_{\\mathrm{eq}} = C[R]_{\\mathrm{tot}} $$\n$$ [AR]_{\\mathrm{eq}} = \\frac{C [R]_{\\mathrm{tot}}}{K_D + C} $$\nThe fraction of receptor occupancy at equilibrium, $\\theta_{\\mathrm{eq}}$, is defined as $\\frac{[AR]_{\\mathrm{eq}}}{[R]_{\\mathrm{tot}}}$. Substituting the expression for $[AR]_{\\mathrm{eq}}$:\n$$ \\theta_{\\mathrm{eq}} = \\frac{1}{[R]_{\\mathrm{tot}}} \\left( \\frac{C [R]_{\\mathrm{tot}}}{K_D + C} \\right) = \\frac{C}{K_D + C} $$\n\nNext, we derive the time-dependent occupancy, $\\theta(t)$. The rate of change of the complex concentration, $[AR]$, is described by the following ordinary differential equation (ODE):\n$$ \\frac{d[AR]}{dt} = k_{\\mathrm{on}}[A][R] - k_{\\mathrm{off}}[AR] $$\nUsing the assumptions that $[A] = C$ (constant) and $[R] = [R]_{\\mathrm{tot}} - [AR]$ (conservation of receptors, since synthesis and internalization are negligible), the ODE becomes:\n$$ \\frac{d[AR]}{dt} = k_{\\mathrm{on}}C([R]_{\\mathrm{tot}} - [AR]) - k_{\\mathrm{off}}[AR] $$\n$$ \\frac{d[AR]}{dt} = k_{\\mathrm{on}}C[R]_{\\mathrm{tot}} - (k_{\\mathrm{on}}C + k_{\\mathrm{off}})[AR] $$\nTo find the equation for the fractional occupancy $\\theta(t) = \\frac{[AR](t)}{[R]_{\\mathrm{tot}}}$, we divide the entire equation by $[R]_{\\mathrm{tot}}$:\n$$ \\frac{d}{dt}\\left(\\frac{[AR]}{[R]_{\\mathrm{tot}}}\\right) = k_{\\mathrm{on}}C - (k_{\\mathrm{on}}C + k_{\\mathrm{off}})\\frac{[AR]}{[R]_{\\mathrm{tot}}} $$\n$$ \\frac{d\\theta}{dt} = k_{\\mathrm{on}}C - (k_{\\mathrm{on}}C + k_{\\mathrm{off}})\\theta $$\nThis is a first-order linear ODE. Let us define the observed rate constant $k_{\\mathrm{obs}} = k_{\\mathrm{on}}C + k_{\\mathrm{off}}$. The equation is now $\\frac{d\\theta}{dt} = k_{\\mathrm{on}}C - k_{\\mathrm{obs}}\\theta$. We can solve this by separation of variables with the initial condition $\\theta(0) = 0$ (since $[AR](0) = 0$):\n$$ \\int_{0}^{\\theta(t)} \\frac{d\\theta'}{k_{\\mathrm{on}}C - k_{\\mathrm{obs}}\\theta'} = \\int_{0}^{t} dt' $$\n$$ \\left[ -\\frac{1}{k_{\\mathrm{obs}}} \\ln(k_{\\mathrm{on}}C - k_{\\mathrm{obs}}\\theta') \\right]_{0}^{\\theta(t)} = t $$\n$$ -\\frac{1}{k_{\\mathrm{obs}}} \\left( \\ln(k_{\\mathrm{on}}C - k_{\\mathrm{obs}}\\theta(t)) - \\ln(k_{\\mathrm{on}}C) \\right) = t $$\n$$ \\ln\\left(\\frac{k_{\\mathrm{on}}C - k_{\\mathrm{obs}}\\theta(t)}{k_{\\mathrm{on}}C}\\right) = -k_{\\mathrm{obs}}t $$\n$$ 1 - \\frac{k_{\\mathrm{obs}}\\theta(t)}{k_{\\mathrm{on}}C} = \\exp(-k_{\\mathrm{obs}}t) $$\n$$ \\theta(t) = \\frac{k_{\\mathrm{on}}C}{k_{\\mathrm{obs}}} (1 - \\exp(-k_{\\mathrm{obs}}t)) $$\nAs $t \\to \\infty$, $\\exp(-k_{\\mathrm{obs}}t) \\to 0$, so $\\theta(t) \\to \\frac{k_{\\mathrm{on}}C}{k_{\\mathrm{obs}}}$. This is the equilibrium occupancy, $\\theta_{\\mathrm{eq}}$.\n$$ \\theta_{\\mathrm{eq}} = \\frac{k_{\\mathrm{on}}C}{k_{\\mathrm{on}}C + k_{\\mathrm{off}}} = \\frac{C}{C + k_{\\mathrm{off}}/k_{\\mathrm{on}}} = \\frac{C}{C+K_D} $$\nThis matches our previous derivation. Therefore, the time-dependent occupancy is:\n$$ \\theta(t) = \\theta_{\\mathrm{eq}} (1 - \\exp(-k_{\\mathrm{obs}}t)) $$\n\nNow we find the time $t_{0.9}$ required to reach $90\\%$ of the equilibrium occupancy, i.e., $\\theta(t_{0.9}) = 0.9\\,\\theta_{\\mathrm{eq}}$.\n$$ 0.9\\,\\theta_{\\mathrm{eq}} = \\theta_{\\mathrm{eq}} (1 - \\exp(-k_{\\mathrm{obs}}t_{0.9})) $$\n$$ 0.9 = 1 - \\exp(-k_{\\mathrm{obs}}t_{0.9}) $$\n$$ \\exp(-k_{\\mathrm{obs}}t_{0.9}) = 0.1 $$\nTaking the natural logarithm of both sides:\n$$ -k_{\\mathrm{obs}}t_{0.9} = \\ln(0.1) = -\\ln(10) $$\n$$ t_{0.9} = \\frac{\\ln(10)}{k_{\\mathrm{obs}}} = \\frac{\\ln(10)}{k_{\\mathrm{on}}C + k_{\\mathrm{off}}} $$\n\nA small association rate constant, $k_{\\mathrm{on}}$, directly affects the observed rate constant $k_{\\mathrm{obs}} = k_{\\mathrm{on}}C + k_{\\mathrm{off}}$. A smaller $k_{\\mathrm{on}}$ leads to a smaller $k_{\\mathrm{obs}}$, assuming the term $k_{\\mathrm{on}}C$ is not negligible compared to $k_{\\mathrm{off}}$. Since the time to reach any fraction of equilibrium (such as $t_{0.9}$) is inversely proportional to $k_{\\mathrm{obs}}$, a smaller $k_{\\mathrm{on}}$ results in a longer time to reach equilibrium. In other words, slow association kinetics mean that the binding process itself is slow, delaying the achievement of the steady-state level of receptor occupancy.\n\nFinally, we compute $t_{0.9}$ for the given parameters:\n$k_{\\mathrm{on}} = 1.0 \\times 10^{4} \\,\\mathrm{M}^{-1}\\mathrm{s}^{-1}$\n$k_{\\mathrm{off}} = 1.0 \\times 10^{-3} \\,\\mathrm{s}^{-1}$\n$C = 30 \\,\\mathrm{nM} = 30 \\times 10^{-9} \\,\\mathrm{M} = 3.0 \\times 10^{-8} \\,\\mathrm{M}$\n\nFirst, we calculate the product $k_{\\mathrm{on}}C$:\n$$ k_{\\mathrm{on}}C = (1.0 \\times 10^{4} \\,\\mathrm{M}^{-1}\\mathrm{s}^{-1}) \\times (3.0 \\times 10^{-8} \\,\\mathrm{M}) = 3.0 \\times 10^{-4} \\,\\mathrm{s}^{-1} $$\nNext, we calculate the observed rate constant $k_{\\mathrm{obs}}$:\n$$ k_{\\mathrm{obs}} = k_{\\mathrm{on}}C + k_{\\mathrm{off}} = (3.0 \\times 10^{-4} \\,\\mathrm{s}^{-1}) + (1.0 \\times 10^{-3} \\,\\mathrm{s}^{-1}) $$\n$$ k_{\\mathrm{obs}} = (0.3 \\times 10^{-3} \\,\\mathrm{s}^{-1}) + (1.0 \\times 10^{-3} \\,\\mathrm{s}^{-1}) = 1.3 \\times 10^{-3} \\,\\mathrm{s}^{-1} $$\nNow we can calculate $t_{0.9}$ in seconds:\n$$ t_{0.9} = \\frac{\\ln(10)}{k_{\\mathrm{obs}}} = \\frac{\\ln(10)}{1.3 \\times 10^{-3} \\,\\mathrm{s}^{-1}} \\approx \\frac{2.302585}{1.3 \\times 10^{-3}} \\,\\mathrm{s} \\approx 1771.22 \\,\\mathrm{s} $$\nThe problem requires the answer in minutes. We convert seconds to minutes by dividing by $60$:\n$$ t_{0.9} \\text{ (in minutes)} = \\frac{1771.22}{60} \\approx 29.5203 \\,\\mathrm{min} $$\nRounding to three significant figures, the result is $29.5$ minutes.", "answer": "$$\n\\boxed{29.5}\n$$", "id": "4931253"}, {"introduction": "A successful drug requires more than just high-affinity binding; it relies on an intact biological pathway to translate that binding event into a therapeutic outcome. This problem [@problem_id:4931197] challenges you to think like a translational scientist, tracing the consequences of a genetic mutation within the crucial interferon-gamma signaling cascade. By connecting a molecular defect to its impact on antigen presentation, T cell recruitment, and ultimately drug efficacy, you will gain insight into the complex mechanisms of primary resistance to checkpoint blockade therapy.", "problem": "A tumor cell’s transcriptional state reflects upstream receptor-mediated signaling. In the interferon system, Interferon-gamma (IFN-$\\gamma$) binds the interferon-$\\gamma$ receptor, triggering the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway: Janus kinase $1$ (JAK$1$) and Janus kinase $2$ (JAK$2$) phosphorylate Signal Transducer and Activator of Transcription $1$ (STAT$1$), which dimerizes, translocates to the nucleus, and drives expression of interferon-stimulated genes via gamma-activated sequences. These genes include components of antigen processing and presentation for Major Histocompatibility Complex (MHC) class $I$ (for example, transporter associated with antigen processing $1$ and $2$ [TAP$1$ and TAP$2$], proteasome subunits such as PSMB$8$ and PSMB$9$, and MHC class $I$ heavy chains), checkpoint ligands such as Programmed death-ligand $1$ (PD-L$1$; gene symbol CD$274$) via Interferon Regulatory Factor $1$ (IRF$1$), and chemokines that recruit cytotoxic CD$8$-positive T cells, such as C-X-C motif chemokine ligand $9$, $10$, and $11$ (CXCL$9$, CXCL$10$, CXCL$11$). Effector T cell trafficking relies on chemokine gradients, and cytotoxic T lymphocyte recognition requires peptide-MHC class $I$ complexes. Programmed cell death protein $1$ (PD-$1$)/PD-L$1$ checkpoint blockade pharmacologically disrupts inhibitory signaling between T cells and target cells but does not create antigen presentation or chemokine gradients de novo.\n\nConsider a metastatic tumor in which sequencing reveals a truncating loss-of-function mutation in JAK$1$ confined to the cancer cells. Tumor-infiltrating lymphocytes (TILs) secrete abundant IFN-$\\gamma$, yet tumor cells fail to phosphorylate STAT$1$ upon IFN-$\\gamma$ exposure. Using the fundamental definitions above (ligand-receptor initiated JAK-STAT signaling, transcriptional induction of interferon-stimulated genes, requirements for antigen presentation and T cell recruitment), reason from first principles which combined pattern is most consistent for the cancer cells with respect to: antigen presentation via MHC class $I$, induction of PD-L$1$ on the tumor cell surface, recruitment of effector CD$8$-positive T cells, and the likely pharmacologic response to PD-$1$/PD-L$1$ checkpoint inhibitor therapy.\n\nChoose the single best option.\n\nA. Antigen presentation decreases; PD-L$1$ induction decreases; T cell recruitment decreases; response to PD-$1$/PD-L$1$ blockade is poor.\n\nB. Antigen presentation decreases; PD-L$1$ induction increases; T cell recruitment decreases; response to PD-$1$/PD-L$1$ blockade is poor.\n\nC. Antigen presentation is unchanged; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.\n\nD. Antigen presentation increases; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.\n\nE. Antigen presentation decreases; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.", "solution": "The user wants me to solve a problem in pharmacology and cancer immunotherapy.\n\n### Step 1: Extract Givens\n\nThe problem statement provides the following information:\n-   **Signaling Pathway:** Interferon-gamma (IFN-$\\gamma$) binds the interferon-$\\gamma$ receptor, activating the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway.\n-   **Mechanism:** Janus kinase $1$ (JAK$1$) and Janus kinase $2$ (JAK$2$) phosphorylate Signal Transducer and Activator of Transcription $1$ (STAT$1$).\n-   **STAT1 Action:** Phosphorylated STAT$1$ dimerizes, translocates to the nucleus, and induces transcription of interferon-stimulated genes (ISGs) by binding to gamma-activated sequences (GAS).\n-   **Key ISGs and their functions:**\n    -   **Antigen Presentation:** Components for Major Histocompatibility Complex (MHC) class $I$ presentation (e.g., transporter associated with antigen processing $1$ and $2$ [TAP$1$, TAP$2$], proteasome subunits PSMB$8$ and PSMB$9$, and MHC class $I$ heavy chains).\n    -   **Checkpoint Ligand:** Programmed death-ligand $1$ (PD-L$1$; gene symbol CD$274$), via Interferon Regulatory Factor $1$ (IRF$1$).\n    -   **T Cell Recruitment:** Chemokines C-X-C motif chemokine ligand $9$, $10$, and $11$ (CXCL$9$, CXCL$10$, CXCL$11$) recruit cytotoxic CD$8$-positive T cells.\n-   **Immune Response Requirements:**\n    -   Effector T cell trafficking depends on chemokine gradients.\n    -   Cytotoxic T lymphocyte recognition requires peptide-MHC class $I$ complexes.\n-   **Pharmacology:** Programmed cell death protein $1$ (PD-$1$)/PD-L$1$ checkpoint blockade disrupts inhibitory signaling but does not create antigen presentation or chemokine gradients de novo.\n-   **Specific Scenario:**\n    -   A metastatic tumor has a truncating loss-of-function mutation in `JAK1` in the cancer cells.\n    -   Tumor-infiltrating lymphocytes (TILs) secrete abundant IFN-$\\gamma$.\n    -   Tumor cells fail to phosphorylate STAT$1$ upon IFN-$\\gamma$ exposure.\n-   **Question:** Determine the combined pattern for the cancer cells with respect to:\n    1.  Antigen presentation via MHC class $I$.\n    2.  Induction of PD-L$1$ on the tumor cell surface.\n    3.  Recruitment of effector CD$8$-positive T cells.\n    4.  Likely pharmacologic response to PD-$1$/PD-L$1$ checkpoint inhibitor therapy.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientifically Grounded:** The description of the IFN-$\\gamma$/JAK-STAT signaling pathway, its downstream targets (ISGs), and its role in cancer immunity is factually correct and represents a fundamental concept in immuno-oncology. The roles of MHC class $I$, PD-L$1$, and chemokines are accurately described.\n-   **Well-Posed:** The problem is well-posed. It presents a specific genetic lesion (loss-of-function `JAK1` mutation) within a clearly defined biological pathway and asks for the logical consequences. The givens are sufficient to deduce a unique outcome.\n-   **Objective:** The language is technical, precise, and free of subjectivity.\n\nThe problem is scientifically sound, internally consistent, and clearly stated. It does not violate any of the invalidity criteria. Therefore, the problem is **valid**.\n\n### Step 3: Derivation from First Principles\n\nThe analysis begins with the central defect: a truncating loss-of-function mutation in `JAK1` in the cancer cells.\n\n1.  **Impact on the Signaling Cascade:** The problem states that IFN-$\\gamma$ signaling requires both JAK$1$ and JAK$2$ to phosphorylate STAT$1$. The loss of JAK$1$ function breaks this cascade at its inception. Even though abundant IFN-$\\gamma$ is present (from TILs) and binds its receptor, the signal cannot be transduced downstream because one of the essential kinases is inactive. The problem explicitly confirms this by stating that \"tumor cells fail to phosphorylate STAT$1$ upon IFN-$\\gamma$ exposure.\"\n\n2.  **Impact on Gene Transcription:** Since STAT$1$ is not phosphorylated, it cannot dimerize, translocate to the nucleus, or bind to GAS elements to activate the transcription of ISGs. Consequently, the entire program of IFN-$\\gamma$-stimulated gene expression is abolished in the cancer cells.\n\n3.  **Downstream Consequences:** We can now deduce the state of the four specified components, all of which depend on ISG expression.\n\n    -   **Antigen presentation via MHC class I:** The machinery for processing and presenting antigens on MHC class $I$ (e.g., `TAP1`, `TAP2`, `PSMB8`, `PSMB9`) is composed of ISGs. Without `STAT1` signaling, the expression of these genes will not be upregulated. This results in a deficient antigen presentation pathway. Therefore, **antigen presentation decreases**.\n\n    -   **Induction of PD-L1:** `PD-L1` is a critical ISG, whose expression on tumor cells is a major mechanism of adaptive immune resistance. Its induction is dependent on the `STAT1` pathway. With the `JAK1` mutation, IFN-$\\gamma$ cannot induce `PD-L1` expression. Therefore, **`PD-L1` induction decreases**. The tumor cells will be `PD-L1`-negative or `PD-L1`-low, failing to upregulate it in response to the inflammatory microenvironment.\n\n    -   **Recruitment of effector CD8-positive T cells:** Chemokines such as `CXCL9`, `CXCL10`, and `CXCL11` are ISGs that create a chemical gradient to attract `CD8`+ T cells to the tumor site. Since the cancer cells cannot produce these chemokines in response to IFN-$\\gamma$, the gradient will be absent or severely diminished. Therefore, **T cell recruitment decreases**. This leads to a non-inflamed or \"cold\" tumor microenvironment, with few T cells present.\n\n    -   **Likely pharmacologic response to PD-1/PD-L1 checkpoint inhibitor therapy:** For `PD-1`/`PD-L1` blockade to be effective, several conditions must be met. The tumor must be recognized and infiltrated by T cells, and the `PD-1`/`PD-L1` axis must be a key mechanism of immunosuppression. In this scenario:\n        -   T cell recognition is impaired due to decreased MHC class $I$ presentation.\n        -   T cell infiltration is impaired due to decreased chemokine production.\n        -   The target of the therapy, `PD-L1`, is not being induced on the cancer cells. The drug is designed to block this interaction, but the interaction itself is absent.\n\n        The tumor is effectively invisible to the immune system and lacks the target of the drug. This is a classic mechanism of primary resistance to checkpoint inhibitors. Therefore, the **response to PD-1/PD-L1 blockade is poor**.\n\n**Summary of Conclusions:**\n-   Antigen presentation: Decreases\n-   PD-L$1$ induction: Decreases\n-   T cell recruitment: Decreases\n-   Response to blockade: Poor\n\n### Option-by-Option Analysis\n\n-   **A. Antigen presentation decreases; PD-L$1$ induction decreases; T cell recruitment decreases; response to PD-$1$/PD-L$1$ blockade is poor.**\n    This option matches every conclusion derived from a step-by-step analysis of the pathway's disruption. The loss of `JAK1` function ablates IFN-$\\gamma$ signaling, leading to reduced antigen presentation, `PD-L1` expression, and T cell-attracting chemokines, all culminating in a poor response to checkpoint inhibitor therapy.\n    **Verdict: Correct.**\n\n-   **B. Antigen presentation decreases; PD-L$1$ induction increases; T cell recruitment decreases; response to PD-$1$/PD-L$1$ blockade is poor.**\n    This option incorrectly states that `PD-L1` induction increases. `PD-L1` is an ISG whose induction is dependent on the now-broken `JAK1`/`STAT1` pathway.\n    **Verdict: Incorrect.**\n\n-   **C. Antigen presentation is unchanged; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.**\n    This option incorrectly claims that antigen presentation is unchanged and T cell recruitment increases. Both are dependent on ISGs and will be decreased. The prediction of an improved response is also incorrect.\n    **Verdict: Incorrect.**\n\n-   **D. Antigen presentation increases; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.**\n    This option incorrectly claims that antigen presentation and T cell recruitment increase. Both are directly impaired by the `JAK1` mutation. The prediction of an improved response is also incorrect.\n    **Verdict: Incorrect.**\n\n-   **E. Antigen presentation decreases; PD-L$1$ induction decreases; T cell recruitment increases; response to PD-$1$/PD-L$1$ blockade improves.**\n    This option incorrectly claims that T cell recruitment increases. This is contradicted by the lack of chemokine production. The prediction of an improved response is also incorrect.\n    **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4931197"}]}